Tag: revenues

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Jewelry Market size & share revenue was valued at approximately USD 382 Billion in 2025 and is expected to reach USD 403 Billion in 2026 and is expected to reach around USD 659 Billion by 2035, at a CAGR of 5.6% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Harry Winston, Dora International, Malabar Gold & Diamonds, Pandora, Louis Vuitton SE, Chow Tai Fook, GRAFF, Richemont, Signet Jewelers Ltd., H. Stern, Swarovski AG, Damiani, Blue Nile, Buccellati, De Beers, Jacob & Co., Tiffany & Co., Fame Diamonds, Gemco Designs, Mauboussin and others.

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A ordinary shares of Sportradar Group AG (NASDAQ: SRAD) between November 7, 2024 and April 21, 2026, inclusive (the “Class Period”), of the important July 17, 2026 lead plaintiff deadline.

Royal Uranium Approval Expected to Advance Company's Potential Transformation into a Diversified Energy Platform

GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading advanced air mobility (“AAM”) technology platform company, today announced its unaudited financial results for the first quarter ended March 31, 2026.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Generic Drug Market size & share revenue was valued at approximately USD 491.35 Billion in 2024 and is expected to reach USD 519.11 Billion in 2025 and is expected to reach around USD 926.54 Billion by 2034, at a CAGR of 6.55% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Alkem Laboratories Limited, Teva Pharmaceutical Industries Limited, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Mylan N.V., Lupin Limited, STADA Arzneimittel AG, Hikma Pharmaceuticals plc, Torrent Pharmaceuticals Ltd., Endo International plc, Aurobindo Pharma Limited, Sawai Pharmaceutical Co. Ltd., Mallinckrodt plc, Amneal Pharmaceuticals Inc and others.

First Quarter Revenue Grows 50% to $52.8 Million; Net Income Increases 66% to $2.1 Million with Adjusted EBITDA Up 71% to $4.9 Million; Cash Position Grows to $24.4 Million

Did you buy SRAD Class A ordinary shares between November 7, 2024, and April 21, 2026?